Remzi KARADAĞ, Cemile KOCA, Yüksel TOTAN, Ramazan YAĞCI, Murat AYDIN, Ayşe Serap KARADAĞ, Gülfer AKBAY, Meral EKŞİOĞLU, Ramazan YİĞİTOĞLU

Aktif ve inaktif Behçet hastalarında serum İL-6, İL-8, TNF- α, C reaktif protein ve ısı şok protein 70 düzeylerinin karşılaştırılması

Amaç: Bu çalışmanın amacı, aktif ve inaktif Behçet hastalarında serum İL-6, İL-8, TNF-α, CRP ve HSP 70 düzeyleriniaraştırmaktır.Yöntem ve gereç: Çalışmaya Uluslararası Çalışma Grubunu kriterlerine gore Behçet hastalığı tanısı almış 50 hasta alındı.Bunların 26’sı aktif ve 24’ü inaktif hastalığa sahipti. Kontrol grubu yaş ve cinsiyet olarak çalışma grubuna benzeyen 25sağlıklı bireyden oluşmaktaydı. Serum İL-6, İL-8, TNF-α, CRP ve HSP 70 düzeyleri ölçüldü.Bulgular: Ortalama serum İL-6, İL-8, TNF-α ve CRP düzeyleri aktif hastalığı olanlarda, inaktif hastalığı olanlar ve kontrolgrubuna göre anlamlı şekilde yüksek bulundu ( hepsinde, P < 0,05). Ortalama serum HSP 70 düzeyi aktif hastalığıolanlarda kontrol grubuna göre anlamlı şekilde yüksek iken (P = 0,02), inaktif hastalığı olanlarda kontrol grubuna göresınırda anlamlı yüksek bulundu (P = 0,044). Bununla birlikte aktif ve inaktif hastalar arasında anlamlı fark tespit edilmedi(P = 0,93).Sonuç: Aktif Behçet hastalarında serum serum İL-6, İL-8, TNF-α ve CRP düzeyleri artmaktadır. HSP 70 düzeyi aktifhastalarda belirgin olmak üzere hem aktif hem de inaktif hasta grubunda kontrol grubuna göre yüksek bulunmaktadır.Bu da, HSP 70’in Behçet hastalığının kronik seyrinde rol aldığını ve inaktif hastalık fazında HSP 70 düzeyleri normaldeğerlerine kadar yeterince düşmediğini göstermektedir.

Anahtar Kelimeler:

Behçet hastalığı, kemokin, C-reaktif protein, sitokin, ısı şok protein, interlökin

Comparison of serum levels of IL-6, IL-8, TNF-α, C reactive protein and heat shock protein 70 in patients with active or inactive Behçet’s disease

The aim of this study was to elucidate serum levels of IL-6, IL-8, TNF-a, CRP, and HSP 70 in patients with active or inactive Behçet's disease. Materials and methods: The study included 50 patients who met the International Study Group criteria for Behçet's disease. Of these, 26 had active disease and 24 had inactive disease. The control group was comprised of 25 age- and sex-matched healthy participants. Serum levels of IL-6, IL-8, TNF-a, CRP, and HSP 70 were measured. Results: In patients with active disease, significantly higher mean serum levels of IL-6, IL-8, TNF-a, and CRP were found compared to patients with inactive disease or in controls (overall, P < 0.05). In patients with active disease, the mean serum level of HSP 70 was significantly higher than that of the control group (P = 0.02). In patients with inactive disease it was higher compared to the controls but with a significance level close to 0.05 (P = 0.044). However, HSP 70 levels did not differ significantly between patients with active disease and patients with inactive disease (P = 0.93). Conclusion: The results of our study suggest that serum IL-6, IL-8, TNF-a, and CRP levels are increased in patients with active Behçet's disease. HSP 70 levels in both active and inactive disease groups were higher than in controls, though it was significant only in the active group. This suggests that HSP 70 has a role in the chronic nature of Behçet's disease, with HSP 70 expression possibly not falling to normal levels in the inactive phase of the disease.

Keywords:

chemokine, C-reactive protein, cytokine, heat shock protein, interleukin, Behçet’s disease,

PDF

___

Kaufmann SHE. Heat shock proteins and the immune response. Immunol Today 1990; 11: 129-36.
Direskeneli H. Behçet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001; 60: 996- 1002.
Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000; 12: 1539-46.
Kitamei H, Kitaichi N, Yoshida K, Nakai A, Fujimoto M, Kitamura M et al. Association of heat shock protein 70 induction and the amelioration of experimental autoimmune uveoretinitis in mice. Immunobiology 2007; 212: 11-8.
Yanaka A, Zhang S, Sato D, Tauchi M, Suzuki H, Shibahara T et al. Geranylgeranylacetone protects the human gastric mucosa from diclofenac-induced injury via induction of heat shock protein 70. Digestion 2007; 75: 148-55.
Zheng Z, Kim JY, Ma H, Lee JE, Yenari MA. Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke. J Cereb Blood Flow Metab 2008; 28: 53-63.
Malago JJ, Koninkx JF, Tooten PC, van Liere EA, van Dijk JE. Anti-inflammatory properties of heat shock protein 70 and butyrate on Salmonella-induced interleukin-8 secretion in enterocyte-like Caco-2 cells. Clin Exp Immunol 2005; 141: 62- 71.
Luo X, Zuo X, Zhou Y, Zhang B, Shi Y, Liu M et al. Extracellular heat shock protein 70 inhibits tumour necrosis factor-alpha induced proinflammatory mediator production in fibroblast- like synoviocytes. Arthritis Res Ther 2008; 10: R41.
Moseley PL. Heat shock proteins and the inflammatory response. Ann N Y Acad Sci 1998; 856: 206-13.
Todryk SM, Gough MJ, Pockley AG. Facets of heat shock protein 70 show immunotherapeutic potential. Immunology 2003; 110: 1-9.
International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet 1990; 335: 1078-80.
Gürbüz O, Ozdemir Y, Coşar CB, Kural G. Lipoprotein (a) in Behçet’s disease as an indicator of disease activity and in thrombotic complications. Eur J Ophthalmol 2001; 11: 62-5.
Müftüoğlu AU, Yazici H, Yurdakul S, Tüzün Y, Pazarli H, Güngen G et al. Behçet’s disease. Relation of serum C reactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol 1986; 25: 235-9.
Bodur H, Borman P, Ozdemir Y, Atan C, Kural G. Quality of life and life satisfaction in patients with Behçet’s disease: relationship with disease activity. Clin Rheumatol 2006; 25: 329- 33.
Pay S, Simşek I, Erdem H, Dinç A. Immunopathogenesis of Behçet’s disease with special emphasize on the possible role of antigen presenting cells. Rheumatol Int 2007; 27: 417-24.
Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992; 62: 60-5.
al-Dalaan A, al-Sedairy S, al-Balaa S, al-Janadi M, Elramahi K, Bahabri S et al. Enhanced interleukin 8 secretion in circulation of patients with Behçet’s disease. J Rheumatol 1995; 22: 904-7.
Luscinskas FW, Kiely JM, Ding H, Obin MS, Hébert CA, Baker JB et al. In vitro inhibitory effect of IL-8 and other chemoattractants on neutrophil-endothelial adhesive interactions. J Immunol 1992; 149: 2163-71.
Sahin S, Akoğlu T, Direskeneli H, Sen LS, Lawrence R. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet’s disease. Ann Rheum Dis 1996; 55: 128-33.
Balkwill FR. Tumour necrosis factor. Br Med Bull 1989; 45: 389- 400.
de Smet MD, Ramadan A. Circulating antibodies to inducible heat shock protein 70 in patients with uveitis. Ocul Immunol Inflamm 2001; 9: 85-92.